Skip to Main content Skip to Navigation
Journal articles

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

Nathalie Eymard 1 Vitaly Volpert 2, 3 Polina Kurbatova 4 Nikolai Bessonov 5 Kayode Ogungbenro 6 Leon Aarons 6 Perrine Janiaud 7 Patrice Nony 7 Agathe Bajard 8 Sylvie Chabaud 8 Yves Bertrand 9 Behrouz Kassaï 10 Catherine Cornu 10
1 ICJ - Institut Camille Jordan [Villeurbanne]
2 DRACULA - Multi-scale modelling of cell dynamics : application to hematopoiesis
CGPhiMC - Centre de génétique et de physiologie moléculaire et cellulaire, Inria Grenoble - Rhône-Alpes, ICJ - Institut Camille Jordan [Villeurbanne]
3 MMCS - Modélisation mathématique, calcul scientifique
ICJ - Institut Camille Jordan [Villeurbanne]
4 LBBE - Laboratoire de Biométrie et Biologie Evolutive - UMR 5558
5 Institute of Mechanical Engineering Problems
6 Centre for Applied Pharmacokinetic Research
7 Evaluation et modélisation des effets thérapeutiques
Département biostatistiques et modélisation pour la santé et l'environnement [LBBE]
8 UBET - Unité de Biostatistique et d'Evaluation des Thérapeutiques
9 ICMUB - Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon]
10 CIC CHU Lyon (inserm)
Abstract : T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatment duration that could be tested in a future clinical trial. We developed a mathematical model of virtual patients with T-LBL in order to obtain a proportion of virtual relapses close to the one observed in the real population of patients from the EuroLB database. Our simulations reproduced a 2-year follow-up required to study the onset of the disease, the treatment of the acute phase and the maintenance treatment phase.
Keywords : mathematical modelling T-cell lymphoblastic lymphoma cancer thymus randomized controlled clinical trial chemotherapy
Document type :
Journal articles
Complete list of metadata

Cited literature [40 references]  Display  Hide  Download
https://hal.archives-ouvertes.fr/hal-01568372
Contributor : Vitaly Volpert <>
Submitted on : Tuesday, July 25, 2017 - 11:39:51 AM
Last modification on : Tuesday, July 20, 2021 - 5:20:07 PM

File

Vignette du document
dqw019.pdf
Files produced by the author(s)

Identifiers

Collections

CNRS | EC-LYON | INSMI | TDS-MACS | CGPHIMC | UNIV-BOURGOGNE | BIOENVIS | UNIV-ST-ETIENNE | INC-CNRS | INRIA | ICMUB | INSERM | ICJ | INSA-LYON | UNIV-LYON1 | INSA-GROUPE | ICJ-MMCS | UDL

Citation

Nathalie Eymard, Vitaly Volpert, Polina Kurbatova, Nikolai Bessonov, Kayode Ogungbenro, et al.. Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients. Mathematical Medicine and Biology, Oxford University Press (OUP), 2017, ⟨10.1093/imammb/dqw019⟩. ⟨hal-01568372⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

1046

Files downloads

841